Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.5.0.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 12 Months Ended
Oct. 16, 2012
May 31, 2016
May 31, 2015
Commitments and Contingencies [Line Items]      
Asset purchase, cash paid $ 3,500,000    
Asset Purchase Agreement Aggregate Consideration Paying Period   10 years  
Payment to acquire other assets   $ 1,500,000  
Accrued milestone payments     $ 2,500,000
Milestone Payments      
Commitments and Contingencies [Line Items]      
Royalty on every net sales   5.00%  
Development Milestone Payments      
Commitments and Contingencies [Line Items]      
Asset Purchase Agreement Aggregate Consideration Paying Period   10 years  
Payment to acquire other assets   $ 1,000,000  
Minimum annual license maintenance fees   150,000  
Project Work Order      
Commitments and Contingencies [Line Items]      
Payments for Fees   1,953,000  
Unamortized clinical trial fees   1,711,000  
Project Work Order | Termination of Any One Clinical Trial | Minimum      
Commitments and Contingencies [Line Items]      
financial penalties   100,000  
Project Work Order | Termination of Any One Clinical Trial | Maximum      
Commitments and Contingencies [Line Items]      
financial penalties   400,000  
Project Work Order | Termination of All Clinical Trials | Minimum      
Commitments and Contingencies [Line Items]      
financial penalties   500,000  
Project Work Order | Termination of All Clinical Trials | Maximum      
Commitments and Contingencies [Line Items]      
financial penalties   1,600,000  
First dosing in a U.S. Phase 3 trial or non-US equivalent | Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments   1,500,000  
First dosing in a U.S. Phase 3 trial or non-US equivalent | Development Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments   1,000,000  
First US new drug application approval by the FDA or other non-U.S. approval | Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments   5,000,000  
Biologic License Application with the FDA or non-U.S. equivalent regulatory body | Development Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments   500,000  
FDA approval or approval by another non-U.S. equivalent regulatory body | Development Milestone Payments      
Commitments and Contingencies [Line Items]      
Potential future milestone and royalties payments   $ 500,000  
Royalty on every net sales   7.50%